Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesBortezomib in the management of multiple myeloma
Cancer Management and Research, 09/11/09
Laubach JP et al. – Multiple myeloma (MM) is a B–cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment–related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.
Related Articles
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Blood, 11/02/09
Relevance Score: 89%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 89%
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 10/01/09
Relevance Score: 89%
VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III Vista study
Journal of Clinical Oncology, 10/29/09
Relevance Score: 87%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09
High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations
Haematologica, 12/19/09
Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
Annals of Hematology, 12/18/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/20/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/20/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09
Sponsor
Article Search
Sponsor
Sponsor